Functional Imaging and Reading Deficit in Children With NF1
- Conditions
- Neurofibromatosis Type 1
- Interventions
- Other: Neuropsychological assessmentsRadiation: morphological and functional MRI (fMRI)Genetic: genetic analysis
- Registration Number
- NCT02422732
- Lead Sponsor
- University Hospital, Toulouse
- Brief Summary
A monocenter pilot study on the acceptability and feasibility of a functional MRI protocol in children with NF1 with or without reading disabilities.
- Detailed Description
The principal aim of the study is to highlight the activation of brain area involved phonological and visuo-spatial processing in children with NF1 with or without reading disabilities.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 25
-
Age included between 8 and 12 years
-
Child presenting a type 1 neurofibromatosis according to 2 criteria in the following criteria list :
- At least 6 café au lait spots
- 2 or more neurofibromas or 1 plexiform neurofibroma
- axillary or inguinal freckling
- 1 optic nerf glioma
- 2 or more Lisch nodules
- 1 osseous lesion as sphenoid dysplasia or thinning of the long bone cortex with or without pseudarthrosis
- 1 A first degree relative (parent, sibling, or offspring) with NF1 by the above criteria
-
Membership in a national insurance
-
Consent of the child and the parents
- Mental retardation (QI T < 70)
- Treated or untreated epilepsy
- Visual deficit (visual Acuteness < 4/10
- Presence of a symptomatic optic glioma
- Presence of a brain tumor.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Children with reading disability genetic analysis Children with NF1, with reading disability if their performances on reading assessment (Alouette Test) present a delay of at least 18 months, will have Neuropsychological assessments, morphological and functional MRI (fMRI) and genetic analysis Children without reading disability Neuropsychological assessments Children with NF1, without reading disability if their performances on reading assessment (Alouette Test) present a less than 18-month delay, will have Neuropsychological assessments, morphological and functional MRI (fMRI) and genetic analysis. Children without reading disability morphological and functional MRI (fMRI) Children with NF1, without reading disability if their performances on reading assessment (Alouette Test) present a less than 18-month delay, will have Neuropsychological assessments, morphological and functional MRI (fMRI) and genetic analysis. Children with reading disability morphological and functional MRI (fMRI) Children with NF1, with reading disability if their performances on reading assessment (Alouette Test) present a delay of at least 18 months, will have Neuropsychological assessments, morphological and functional MRI (fMRI) and genetic analysis Children without reading disability genetic analysis Children with NF1, without reading disability if their performances on reading assessment (Alouette Test) present a less than 18-month delay, will have Neuropsychological assessments, morphological and functional MRI (fMRI) and genetic analysis. Children with reading disability Neuropsychological assessments Children with NF1, with reading disability if their performances on reading assessment (Alouette Test) present a delay of at least 18 months, will have Neuropsychological assessments, morphological and functional MRI (fMRI) and genetic analysis
- Primary Outcome Measures
Name Time Method Percentage of children performing in full the protocol functional MRI day 1 Study the acceptability and feasibility of a functional MRI protocol in children with NF1 with or without reading disabilities.
- Secondary Outcome Measures
Name Time Method blood flow in milliliters per minute day 1 Comparison of brain activations involved in phonological and visuo-spatial processing in 2 groups in children with NF1.
1 group with reading disability and 1 group without reading disability Search for a link between the presence of a large deletion of the gene and learning disorders.
Trial Locations
- Locations (1)
CHU Toulouse
🇫🇷Toulouse, France